Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
